VISCHER advises BiognoSYS AG, a leading company acting in the field of next-generation proteomics, in a significant series C funding from a corporate investment fund. The funds will be invested in establishing the business development and a new US service operation as well as in the development of new workflows and products for high-content protein analysis. The VISCHER Team was led by Dr. Matthias Staehelin (Partner) and Dania Salvisberg-Schneider (Senior Associate), both Corporate.